(Q37307777)

19 August 2017

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials (English)

1 reference

multicenter clinical trial

19 August 2017

0 references

0 references

0 references

0 references

Linda A DiMeglio

4

0 references

Paolo Pozzilli

Paolo Pozzilli

25

0 references

Luis Castaño

Luis Castaño

28

0 references

Thomas Mandrup-Poulsen

Thomas Mandrup-Poulsen

32

0 references

Didac Mauricio

Didac Mauricio

26

0 references

Robin Goland

6

Robin Goland

1 reference

19 August 2017

12

Desmond Schatz

1 reference

19 August 2017

15

Jeffrey P Krischer

1 reference

19 August 2017

8

Kevan C Herold

1 reference

19 August 2017

7

Carla J Greenbaum

1 reference

19 August 2017

14

Darrell M Wilson

1 reference

19 August 2017

16

Jay S Skyler

1 reference

19 August 2017

3

Dorothy J Becker

1 reference

19 August 2017

Antoinette Moran

1

1 reference

19 August 2017

Brian Bundy

2

1 reference

19 August 2017

Stephen E Gitelman

5

1 reference

19 August 2017

Jennifer B Marks

9

1 reference

19 August 2017

Philip Raskin

10

1 reference

19 August 2017

Srinath Sanda

11

1 reference

19 August 2017

Diane K Wherrett

13

1 reference

19 August 2017

Type 1 Diabetes TrialNet Canakinumab Study Group

17

1 reference

19 August 2017

Linda Pickersgill

18

1 reference

19 August 2017

Eelco de Koning

19

1 reference

19 August 2017

Anette-G Ziegler

20

1 reference

19 August 2017

Bernhard Böehm

21

1 reference

19 August 2017

Klaus Badenhoop

22

1 reference

19 August 2017

Nanette Schloot

23

1 reference

19 August 2017

Jens Friis Bak

24

1 reference

19 August 2017

Marc Y Donath

27

1 reference

19 August 2017

Ana Wägner

29

1 reference

19 August 2017

Hans Henrik Lervang

30

1 reference

19 August 2017

Hans Perrild

31

1 reference

19 August 2017

AIDA Study Group

33

1 reference

19 August 2017

language of work or name

English

0 references

publication date

5 April 2013

1 reference

19 August 2017

1 reference

19 August 2017

381

1 reference

19 August 2017

9881

1 reference

19 August 2017

1905-1915

1 reference

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Blockade of interleukin 1 in type 1 diabetes mellitus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

GAD treatment and insulin secretion in recent-onset type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Mouse islet cell lysis mediated by interleukin-1-induced Fas.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Insulin secretion in type 1 diabetes

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Gene Expression in Peripheral Blood Mononuclear Cells from Children with Diabetes

3 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3827771

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

3 December 2018

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960023-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960023-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0140-6736(13)60023-9

1 reference

release_mo6vrj4r6nclxbsngtgos4zcjm

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mo6vrj4r6nclxbsngtgos4zcjm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 August 2017

1 reference